NCT06305299View on ClinicalTrials.gov

Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells

PHASE1RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 29, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Ovary NeoplasmOvarian CancerEpithelial Ovarian CancerRecurrent
Interventions
BIOLOGICAL

iC9-CAR.B7-H3 T cells

iC9-CAR.B7-H3 T cells will then be administered intraperitoneally

DRUG

Cyclophosphamide

cyclophosphamide 300 mg/m2 IV will be given.

DRUG

Fludarabine

fludarabine 30 mg/m2 IV will be given.

Trial Locations (1)

27599

RECRUITING

Lineberger Comprehensive Cancer Center, Chapel Hill

All Listed Sponsors
lead

UNC Lineberger Comprehensive Cancer Center

OTHER